Research Paper Volume 14, Issue 13 pp 5590—5610
A pan-cancer analysis confirms PTPN11’s potential as a prognostic and immunological biomarker
Figure 3. Mutation’s characteristic of PTPN11 in a variety of TCGA cancers. The cBioPortal application displays the frequency of PTPN11 mutations with mutation type (A) and mutation locations (B) in TCGA cancers. (C) The cBioPortal tool was utilized to evaluate the possible relation between PTPN11 mutation state and overall, disease-specific, disease-free, and progression-free survival of LUSC patients.